Cancers, Vol. 13, Pages 5301: Identification of MicroRNA –mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes

Cancers, Vol. 13, Pages 5301: Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes Cancers doi: 10.3390/cancers13215301 Authors: Robert A. Szczepaniak Sloane Michael G. White Russell G. Witt Anik Banerjee Michael A. Davies Guangchun Han Elizabeth Burton Nadim Ajami Julie M. Simon Chantale Bernatchez Lauren E. Haydu Hussein A. Tawbi Jeffrey E. Gershenwald Emily Keung Merrick Ross Jennifer McQuade Rodabe N. Amaria Khalida Wani Alexander J. Lazar Scott E. Woodman Linghua Wang Miles C. Andrews Jennifer A. Wargo Metastatic melanoma is a deadly malignancy with poor outcomes historically. Immuno-oncology (IO) agents, targeting immune checkpoint molecules such as cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1), have revolutionized melanoma treatment and outcomes, achieving significant response rates and remarkable long-term survival. Despite these vast improvements, roughly half of melanoma patients do not achieve long-term clinical benefit from IO therapies and there is an urgent need to understand and mitigate mechanisms of resistance. MicroRNAs are key post-transcriptional regulators of gene expression that regulate many aspects of cancer biology, including immune evasion. We used network analysis to define two core microRNA–mRNA networks in melanoma tissues and cell lines corresponding to ‘MITF-low’ and ‘Keratin’ tran...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research